Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) EBIT : $-748.8 Mil (TTM As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co EBIT?

Biohaven Pharmaceutical Holding Co's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2022 was $-398.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2022 was $-748.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biohaven Pharmaceutical Holding Co's annualized ROC % for the quarter that ended in Jun. 2022 was -380.61%. Biohaven Pharmaceutical Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -10,536.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biohaven Pharmaceutical Holding Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -6.75%.

Biohaven Pharmaceutical Holding Co EBIT Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co EBIT Chart

Biohaven Pharmaceutical Holding Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT

Get a 7-Day Free Trial

-126.18

-228.73

-489.10

-672.89

-708.87

Biohaven Pharmaceutical Holding Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EBIT	Get a 7-Day Free Trial															-176.43	-141.85	-158.27	-50.15	-398.57

Competitive Comparison of Biohaven Pharmaceutical Holding Co's EBIT

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biohaven Pharmaceutical Holding Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's EV-to-EBIT falls into.

Biohaven Pharmaceutical Holding Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-748.8 Mil.

Biohaven Pharmaceutical Holding Co (NYSE:BHVN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biohaven Pharmaceutical Holding Co's annualized ROC % for the quarter that ended in Jun. 2022 is calculated as:

	ROC % (Q: Jun. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2022 )	+	Invested Capital (Q: Jun. 2022 ))	/ count )
=	-1158.388 * ( 1 - -0.02% )	/	( (298.494	+	310.325)	/ 2 )
=	-1158.6196776	/	304.4095
=	-380.61 %

where

	Invested Capital		(Q: Mar. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1371.717	-	478.252	-	( 602.475	-	max(0, 576.114	-	1171.085	+	602.475	))
=	298.494

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1386.249	-	573.539	-	( 553.486	-	max(0, 671.956	-	1174.341	+	553.486	))
=	310.325

Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Biohaven Pharmaceutical Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2022		Q: Jun. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1594.26	/	( ( (14.534 + max(-7.5039999999999, 0))	+	(15.727 + max(-51.101, 0)) )	/	2 )
=	-1594.26	/	( ( 14.534	+	15.727 )	/	2 )
=	-1594.26	/	15.1305
=	-10,536.73 %

where Working Capital is:

	Working Capital		(Q: Mar. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(328.342	+	91.281	+	148.987)	-	(478.252	+	0	+	97.862)
=	-7.5039999999999

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(352.449	+	106.561	+	161.845)	-	(573.539	+	0	+	98.417)
=	-51.101

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biohaven Pharmaceutical Holding Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2022 )
	=	-748.832	/	11087.211
	=	-6.75 %

Biohaven Pharmaceutical Holding Co EBIT Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Executives

Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock	officer: Chief Medical Officer	215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart	officer: Chief Financial Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten	officer: Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan	director	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs	director, 10 percent owner	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr	officer: CCO-Migraine & Common Disease	NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile	officer: VP of Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman	officer: Chief Medical Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton	officer: Chief Commercial Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054